JNJ

233.64

+2.97%↑

ABBV

229.09

+3.67%↑

UNH

400.7

+0.87%↑

MRK

123.19

+3.76%↑

AZN

185.59

+1.94%↑

JNJ

233.64

+2.97%↑

ABBV

229.09

+3.67%↑

UNH

400.7

+0.87%↑

MRK

123.19

+3.76%↑

AZN

185.59

+1.94%↑

JNJ

233.64

+2.97%↑

ABBV

229.09

+3.67%↑

UNH

400.7

+0.87%↑

MRK

123.19

+3.76%↑

AZN

185.59

+1.94%↑

JNJ

233.64

+2.97%↑

ABBV

229.09

+3.67%↑

UNH

400.7

+0.87%↑

MRK

123.19

+3.76%↑

AZN

185.59

+1.94%↑

JNJ

233.64

+2.97%↑

ABBV

229.09

+3.67%↑

UNH

400.7

+0.87%↑

MRK

123.19

+3.76%↑

AZN

185.59

+1.94%↑

Home・Listă Acțiuni・Eli Lilly and Co.

Eli Lilly and Co.

Deschisă

SectorSănătate

1,162.33 2.27

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1117.84

Maxim

1165.57

Indicatori cheie
By Trading Economics
Venit	758M 7.4B
Vânzări	507M 20B
P/E Medie Sector	38.458 49.888
EPS	8.55
Randament dividend	0.56
Marjă de profit	37.355
Angajați	50,000
EBITDA	971M 9.4B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+17.5% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.56% 2.38%
Următoarele câștiguri	5 aug. 2026
Data viitoare de dividende	10 iun. 2026
Următoarea dată ex-dividende	14 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	189B 965B
Deschiderea anterioară	1160.06
Închiderea anterioară	1162.33

Sentimentul știrilor

By Acuity

33%

67%

84 / 344 Clasament în Healthcare

Eli Lilly and Co. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

20 mai 2026, 14:24 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly Buys Engage Biologics for Up to $202 Million

2 iun. 2026, 04:01 UTC

Achiziții, Fuziuni, Preluări

M&A Is Back in a Big Way. These Are the Sectors in Play. -- Barrons.com

29 mai 2026, 23:06 UTC

Achiziții, Fuziuni, Preluări

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

26 mai 2026, 12:29 UTC

Achiziții, Fuziuni, Preluări

Lilly Agrees to Buy Trio of Vaccine Developers -- Update

26 mai 2026, 10:35 UTC

Achiziții, Fuziuni, Preluări

Eli Lilly Agrees to Acquire Three Vaccine Developers, Company Says -- WSJ

26 mai 2026, 10:35 UTC

Achiziții, Fuziuni, Preluări

Lilly's Deals Are Worth up to Nearly $4 Billion Combined, Company Says -- WSJ

26 mai 2026, 10:35 UTC

Achiziții, Fuziuni, Preluări

Lilly to Acquire Curevo, LimmaTech and Vaccine Co., Company Says -- WSJ

26 mai 2026, 10:35 UTC

Achiziții, Fuziuni, Preluări

Lilly Agrees to Buy Trio of Vaccine Developers -- WSJ

20 mai 2026, 13:35 UTC

Achiziții, Fuziuni, Preluări

Engage Bio: Eli Lilly Deal Includes Upfront, Milestone Payments >LLY

20 mai 2026, 13:34 UTC

Achiziții, Fuziuni, Preluări

Engage Bio Acquired by Eli Lilly for Up to $202 Million >LLY

7 mai 2026, 09:30 UTC

Câștiguri

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 mai 2026, 12:36 UTC

Câștiguri

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 mai 2026, 10:12 UTC

Câștiguri

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 mai 2026, 09:58 UTC

Câștiguri

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

30 apr. 2026, 20:59 UTC

Acțiuni populare

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30 apr. 2026, 20:12 UTC

Câștiguri

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr. 2026, 16:43 UTC

Câștiguri

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30 apr. 2026, 16:10 UTC

Market Talk

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30 apr. 2026, 15:13 UTC

Câștiguri

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr. 2026, 14:58 UTC

Câștiguri

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30 apr. 2026, 14:53 UTC

Câștiguri

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30 apr. 2026, 14:50 UTC

Câștiguri

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30 apr. 2026, 14:42 UTC

Câștiguri

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30 apr. 2026, 14:39 UTC

Câștiguri

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30 apr. 2026, 14:35 UTC

Câștiguri

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30 apr. 2026, 14:24 UTC

Câștiguri

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30 apr. 2026, 14:17 UTC

Câștiguri

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30 apr. 2026, 13:56 UTC

Câștiguri

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr. 2026, 13:37 UTC

Acțiuni populare

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 apr. 2026, 12:32 UTC

Market Talk

Câștiguri

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

Comparație

Modificare preț

Eli Lilly and Co. Așteptări

Obiectiv de preț

By TipRanks

17.5% sus

Prognoză pe 12 luni

Medie 1,267.57 USD 17.5%

Maxim 1,500 USD

Minim 850 USD

În baza a 23 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEli Lilly and Co. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

23 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 23 analiști care au acordat evaluări ale acțiunilor Eli Lilly and Co. - Dist în ultimele 3 luni.

Sentiment

By Acuity

84 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.